Cellid, Co., Ltd. (299660.KQ)
- Previous Close
3,365.00 - Open
3,365.00 - Bid 3,305.00 x --
- Ask 3,320.00 x --
- Day's Range
3,275.00 - 3,405.00 - 52 Week Range
1,733.00 - 17,310.00 - Volume
120,777 - Avg. Volume
329,245 - Market Cap (intraday)
78.538B - Beta (5Y Monthly) 1.61
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo. Cellid, Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.
www.cellid.co.krRecent News: 299660.KQ
View MorePerformance Overview: 299660.KQ
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 299660.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 299660.KQ
View MoreValuation Measures
Market Cap
79.96B
Enterprise Value
84.07B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.01
Price/Book (mrq)
1.56
Enterprise Value/Revenue
20.18
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-294.33%
Return on Assets (ttm)
-10.70%
Return on Equity (ttm)
-26.74%
Revenue (ttm)
4.17B
Net Income Avi to Common (ttm)
-12.26B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
9.07B
Total Debt/Equity (mrq)
25.73%
Levered Free Cash Flow (ttm)
-24.09B